Roche CEO Severin Schwan called recently launched PD-L1 drug Tecentriq's CHF77m sales figure impressive when presenting the company's third-quarter earnings on Oct. 20. Roche also spotlighted its "comprehensive" immuno-oncology portfolio which is producing "quantity as well as quality" with five product launches in 12 months.
Even as the third programmed-death inhibitor to market, oncology powerhouse Roche reported sales of CHF77m ($77.6m) for its immunotherapy Tecentriq in its first full quarter of sales, with “strong initial uptake.”
Tecentriq (atezolizumab) became the first PD-L1 product on the market after winning FDA approval in May for use in bladder...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Nancy tests Jira ticket SPARC-1036: Make anchor link work on initial page load
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
